Skip to Content

New bispecific antibody with promising efficacy and safety profil for patients with relapsed/refractory Multiple Myeloma

Talquetamab is a bispecific immunoglobulin G4 antibody that binds to CD3 and the novel target GPRC5D to redirect T cells to kill Multiple Myeloma cells. In this MEDtalk, Amrita Krishnan, director of the Judy and Bernard Briskin Center for Multiple Myeloma, City of Hope Cancer Center, Duarte, USA; present promising efficacy and safety data from the first in humanstudy. The study shows, that Talquetamab, have a high clinical response rate and was well-tolerated in patients with relapsed/refractory MM.

Få tilgang til artikkelen

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top